^
    Back
    Association details:
    Biomarker:ALK wild-type
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Libtayo (cemiplimab-rwlc) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Nat Med
    Title:

    Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

    Published date:
    08/25/2022
    Excerpt:
    The results of EMPOWER-Lung 3 demonstrate that cemiplimab in combination with platinum-doublet chemotherapy is a potential first-line treatment option for patients with advanced squamous and non-squamous NSCLC, regardless of PD-L1 expression level and without EGFR, ALK or ROS1 aberrations.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1038/s41591-022-01977-y
    Trial ID:
    EMPOWER-Lung 3